[ad_1]
It should be noted that temporary pauses are common for large medical studies, and the investigation of any dangerous or unexpected reactions is a mandatory part of safety testing.
و .شارت "AstraZeneca" However, the problem is likely a coincidence, as diseases of all kinds can appear in studies of thousands of people.
The group’s general manager, Pascal Sorio, had mentioned in an online conference, and according to statements confirmed by a company spokesperson: "We could still get vaccinated at the end of the year, early next year."As cited "France brush".
Suryo said the company will know before the end of the year if its experimental vaccine protects people from contracting a disease. "COVID-19"But on the condition that you can resume the experiments soon.
“>
Company spokesman Matthew Kent said that in the later stage of the trial, study participants had symptoms consistent with transverse myelitis, a rare inflammation of the spinal cord.
Kent also said: “We don’t know if (transverse myelitis). More tests are now being done as part of the follow-up,” according to the Associated Press.
AstraZeneca reported Tuesday that its “standard review process” has led to the cessation of vaccination to allow for review of safety data.
No details were provided other than saying that one of the participants had an “unexplained illness”.
The vaccine was initially developed by the University of Oxford after the coronavirus pandemic began this year.
Kent noted that an independent panel was reviewing the study’s safety data, before deciding if and when the research could continue.
The study was previously stopped, in July, for several days after one of the participants who received the vaccine developed neurological symptoms, and it turned out to be an undiagnosed case of multiple sclerosis, which has nothing to do with the vaccine.
Late last month, AstraZeneca began recruiting 30,000 people in the United States for its largest study of the vaccine. The vaccine is also being tested in thousands of people in Britain and in smaller studies in Brazil and South Africa.
There are many other vaccines in development against Covid-19 disease.
In context, Dr. Soumya Swaminathan, chief scientist at the World Health Organization, said the United Nations organization was not overly concerned about the temporary pause in the trial of the Oxford and AstraZeneca vaccine, describing it as a “wake-up call” for the world community about the inevitable rise and fall of medical research. .
It should be noted that temporary pauses are common for large medical studies, and the investigation of any dangerous or unexpected reactions is a mandatory part of safety testing.
“It is possible that the problem is a coincidence,” said AstraZeneca, since diseases of all kinds could appear in studies of thousands of people.
The group’s general manager, Pascal Sorio, said in an online conference, according to statements confirmed by a company spokesman: “We can still get a vaccine by the end of the year, early next year,” according to AFP.
Suryo said the company will know before the end of the year if its experimental vaccine protects people from infection with “Covid-19”, but on the condition that it can resume experiments soon.
[ad_2]
